Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is a highly aggressive tumor. Alternative treatment strategies such as oncolytic viral therapy may offer promising treatment options in the future. In this study, the oncolytic efficacy and induction of tumor remission by a genetically engineered Newcastle disease virus [NDV; NDV(F3aa)-GFP; GFP, green fluorescent protein] in malignant pleural mesothelioma is tested and monitored by bioluminescent tumor imaging. The efficacy of NDV(F3aa)-GFP was tested against several mesothelioma cell lines in vitro. Firefly luciferase–transduced MSTO-211H* orthotopic pleural mesothelioma tumor-bearing animals were treated with either single or multiple doses of NDV(F3aa)-GFP at different time points (days 1 and 10) after tumor implantation. Tumor burden was assessed by bioluminescence imaging. Mesothelioma cell lines exhibited dose-dependent susceptibility to NDV lysis in the following order of sensitivity: MSTO-211H > MSTO-211H* > H-2452 > VAMT > JMN. In vivo studies with MSTO-211H* cells showed complete response to viral therapy in 65% of the animals within 14 days after treatment initiation. Long-term survival in all of these animals was >50 days after tumor installation (control animals, <23 d). Multiple treatment compared with single treatment showed a significantly better response (P = 0.005). NDV seems to be an efficient viral oncolytic agent in the therapy of malignant pleural mesothelioma in an orthotopic pleural mesothelioma tumor model. Mol Cancer Ther; 9(10); 2761–9. ©2010 AACR.

[1]  Y. Fong,et al.  Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer , 2010, Journal of Molecular Medicine.

[2]  P. Boukamp,et al.  Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus , 2010, Oncogene.

[3]  H. Hricak,et al.  Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene , 2009, Clinical Cancer Research.

[4]  A. García-Sastre,et al.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  P. Fournier,et al.  Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer , 2008, Methods in molecular biology.

[6]  A. García-Sastre,et al.  Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy , 2008, Molecular Therapy.

[7]  F. Errington,et al.  Oncolytic viruses: a novel form of immunotherapy , 2008, Expert review of anticancer therapy.

[8]  V. Rusch,et al.  Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. , 2008, Human gene therapy.

[9]  H. Pass,et al.  Malignant mesothelioma 2008 , 2008, Current opinion in pulmonary medicine.

[10]  H. Pass,et al.  Current concepts in malignant pleural mesothelioma , 2008, Expert review of anticancer therapy.

[11]  Kathryn E. Luker,et al.  Optical Imaging: Current Applications and Future Directions , 2007, Journal of Nuclear Medicine.

[12]  A. Arnold,et al.  Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy , 2007, Gene Therapy.

[13]  A. García-Sastre,et al.  Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. , 2007, Cancer research.

[14]  Claudio Bianchi,et al.  Malignant mesothelioma: global incidence and relationship with asbestos. , 2007, Industrial health.

[15]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[16]  D. Kirn,et al.  Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. , 2007, Cancer research.

[17]  L. Csatary,et al.  p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell Lines , 2007, Journal of Virology.

[18]  A. Arnold,et al.  Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence , 2006, International journal of cancer.

[19]  S. Krishnamurthy,et al.  Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell Lines , 2006, Journal of Virology.

[20]  A. García-Sastre,et al.  Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. Rusch,et al.  Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses , 2006, The journal of gene medicine.

[22]  B. Robinson,et al.  Gene therapy for malignant mesothelioma: beyond the infant years , 2006, Cancer Gene Therapy.

[23]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Paul Kremer,et al.  Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Weidauer,et al.  Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells , 2004, Cancer Research.

[26]  W. Richards,et al.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. , 2004, The Journal of thoracic and cardiovascular surgery.

[27]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[28]  K. O'Byrne,et al.  The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. , 2004, The Annals of thoracic surgery.

[29]  S. Hotte,et al.  Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.

[30]  P. Fournier,et al.  Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. , 2003, International journal of oncology.

[31]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Elankumaran,et al.  Recombinant Newcastle disease virus as a vaccine vector. , 2003, Poultry science.

[33]  M. Mayo.  A summary of taxonomic changes recently approved by ICTV , 2002, Archives of Virology.

[34]  R. Tsien,et al.  A monomeric red fluorescent protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Fournier,et al.  Induction of Interferon-α and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Human Blood Mononuclear Cells by Hemagglutinin-Neuraminidase but Not F Protein of Newcastle Disease Virus , 2002 .

[36]  H. Kindler,et al.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. , 2002, Seminars in oncology.

[37]  M. Peeples,et al.  Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. , 2001, Cancer letters.

[38]  A. Ardizzoni,et al.  Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. , 2001, Lung cancer.

[39]  B. Robinson,et al.  Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. , 2000, American journal of respiratory cell and molecular biology.

[40]  J. Sinkovics,et al.  Newcastle disease virus (NDV): brief history of its oncolytic strains. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[41]  P. Gregersen,et al.  A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alterations in the CD8 T Cell Repertoire , 1998, Molecular medicine.

[42]  S. Krishnamurthy,et al.  Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. , 1998, The Journal of general virology.

[43]  A. Musk,et al.  Intralesional Cytokine Therapy in Cancer: A Pilot Study of GM‐CSF Infusion in Mesothelioma , 1998, Journal of immunotherapy.

[44]  James M. Wilson,et al.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.

[45]  V. Schirrmacher,et al.  Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  A. Bickford,et al.  Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. , 1995, Microbial pathogenesis.

[47]  N. Millar,et al.  RNA editing in Newcastle disease virus. , 1993, The Journal of general virology.

[48]  G. Sluis‐Cremer,et al.  Asbestos Disease at Low Exposure after Long Residence Time in Amphibole Miners , 1991, Toxicology and industrial health.

[49]  J. Wagner,et al.  Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.

[50]  A. Flanagan,et al.  Propagation of Newcastle Disease Virus in Ehrlich Ascites Cells In Vitro and In vivo.∗ , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[51]  P. Schlag,et al.  Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial , 2008, Cancer Immunology, Immunotherapy.

[52]  Ronald G Blasberg,et al.  In vivo molecular‐genetic imaging , 2002, Journal of cellular biochemistry. Supplement.

[53]  S. Weitzman,et al.  Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. , 1996, Cancer investigation.

[54]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.